The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation

Table 5 Cox regression analyses of clinico-pathological parameters on the Test- and Validation-TMA cohorts

Endpoint	Clinical parameter	Test-TMA cohort				Validation-TMA cohort
		P	Exp(B)	95.0% CI		P	Exp(B)	95.0% CI
		P	Exp(B)	Lower	Upper	P	Exp(B)	Lower	Upper
BCR	Serum PSA level	< 0.001	1.064	1.042	1.086	< 0.001	1.031	1.026	1.036
	Gleason score at RP (6, 3 + 4, 4 + 3, > 8)	< 0.001	2.035	1.631	2.54	< 0.001	1.946	1.778	2.13
	pTNM	< 0.001	4.673	3.133	6.97	< 0.001	2.599	2.202	3.067
	Margin status	< 0.001	2.392	1.517	3.77	< 0.001	2.362	1.955	2.852
Bone metastasis	Serum PSA level	0.051	1.047	1	1.096	0.047	1.018	1	1.036
	Gleason score at RP (6, 3 + 4, 4 + 3, > 8)	0.001	3.159	1.6	6.237	< 0.001	3.333	2.476	4.487
	pTNM	< 0.001	8.396	3.043	23.162	< 0.001	3.882	2.422	6.22
	Margin status	0.125	2.624	0.765	9.008	0.988	0.996	0.569	1.743
PC specific death	Serum PSA level	–	–	–	–	0.046	1.02	1	1.039
	Gleason score at RP (6, 3 + 4, 4 + 3, > 8)	0.001	3.159	1.6	6.237	< 0.001	3.333	2.476	4.487
	pTNM	–	–	–	–	< 0.001	3.263	1.843	5.78
	Margin status	–	–	–	–	0.117	1.689	0.877	0.3252

TMA tissue microarray, 95% CI 95% confidence interval, BCR biochemical recurrence, PSA prostate-specific antigen, RP radical prostatectomy, pTNM pathological staging, PC prostate cancer. Bold indicate significance

ISSN: 1471-2490